BRCA2 Breast Cancer: Erika's Patient Story

This breast cancer diagnosis at a glance

Biomarkers
BRCA2 mutation
Sex
Female
Treatment
surgery, reconstruction and surveillance
Outcome
Care Ongoing

Treatment course, step by step

  1. Genetic counseling/testing after her mother had 2 breast cancer diagnoses and a BRCA2 mutation
  2. Erika tested positive for the same BRCA2 mutation
  3. enhanced surveillance and tamoxifen were discussed as options, but surgical teams recommended risk-reducing surgery because of the family history
  4. preoperative mammogram and MRI showed no signs of cancer
  5. preventive double mastectomy in December with nipple-sparing direct-to-implant reconstruction in 1 operation; surgery lasted about 5.5 hours and drains stayed about 1 week
  6. ongoing hereditary-risk surveillance with annual manual breast exam, CA-125 bloodwork and transvaginal ultrasound every 6 months, yearly dermatology and ophthalmology visits, future colonoscopy, and planned ovarian removal between ages 38 and 40.

What happened, in summary

Erika was in college when her mother was diagnosed with breast cancer for the second time and tested positive for a BRCA2 mutation. Years later, as Erika approached the age her mother had been at her first breast cancer diagnosis, she met with a genetic counselor at NYU Langone. Testing showed that she had inherited the same BRCA2 mutation. The result meant a sharply increased breast cancer risk, plus added ovarian, melanoma, pancreatic, and colon cancer surveillance needs. Erika reviewed several options, including enhanced surveillance with MRI and mammogram every 6 months. Because of her mother’s history of 2 breast cancers, the surgical teams she met recommended a risk-reducing mastectomy. She had both mammogram and MRI before surgery to check for cancer, then underwent a preventive double mastectomy in December with nipple-sparing, direct-to-implant reconstruction in 1 operation. The surgery lasted about 5.5 hours, drains stayed in for about 1 week, and she returned to work after about 3.5 weeks on a reduced schedule. As of June 2026, Erika had no cancer diagnosis and continued long-term hereditary-risk management, including breast exams, ovarian screening with CA-125 and transvaginal ultrasound, dermatology and ophthalmology visits, future colonoscopy, and planned ovary removal between ages 38 and 40.

Where this story comes from

This is a lay summary of an account first published by The Patient Story. Read the original in full

How we source and attribute stories Accuracy and limitations

Similar breast cancer stories

These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer

Search more breast cancer stories